Elutia Inc. Engaging with Investors at Key Conferences
Elutia Inc. (Nasdaq: ELUT) is gearing up to make a notable impression at several upcoming investor conferences, where it will highlight its cutting-edge drug-eluting biomatrix products. As a frontrunner in enhancing the compatibility of medical technology, Elutia is committed to improving the lives of patients who depend on implantable devices. Dr. Randy Mills, the President and CEO, along with CFO Matt Ferguson, will be present to share insights about their strategic initiatives and the overall vision of the company.
Featuring at the H.C. Wainwright Annual Global Investment Conference
On September 9, Elutia will participate in the H.C. Wainwright 26th Annual Global Investment Conference. This event will feature a presentation format and personalized one-on-one meetings, offering investors a unique chance to gain insights directly from the management team. The initial presentation is scheduled to begin at 7:00 a.m. ET and will be available on-demand, making it easy for potential investors to stay updated on Elutia's progress.
One-on-One Meetings Scheduled
The one-on-one meetings are set for September 11, allowing institutional investors to engage directly with Elutia's leadership. These sessions are tailored for investors who want to deepen their understanding of the company’s offerings and future plans.
Participation in Lake Street Capital Markets Best Ideas Growth Conference
Elutia will also be featured at the Lake Street Capital Markets 8th Annual Best Ideas Growth Conference, which will focus on individualized meetings on September 12. This format is particularly beneficial for investors seeking an in-depth discussion about Elutia’s distinctive products and market strategies.
Connecting with Institutional Investors
Institutional investors interested in connecting with Elutia’s management during these conferences are encouraged to reach out through their respective H.C. Wainwright and Lake Street representatives. This effort underscores Elutia's commitment to building relationships with stakeholders who are vital to the company’s success.
Elutia's Mission and Vision
Elutia is more than just a biotech company; it is dedicated to humanizing medicine through innovative solutions. Their drug-eluting biomatrix products are crafted to seamlessly integrate with medical technologies, ensuring a better quality of life for patients. As the demand for such devices continues to rise, Elutia remains focused on its mission of enabling patients to thrive without compromise, embodying the essence of compassionate healthcare.
Contact Information for Investors
For those interested in learning more or making inquiries directly, Matt Steinberg from FINN Partners is available for contact. Investors can reach him via email at matt.steinberg@finnpartners.com.
Frequently Asked Questions
What are the key products of Elutia Inc.?
Elutia Inc. specializes in drug-eluting biomatrix products that enhance patient compatibility with medical devices.
Who will represent Elutia at the upcoming conferences?
Dr. Randy Mills, the President and CEO, along with CFO Matt Ferguson, will represent Elutia at the conferences.
How can investors participate in the conferences?
Investors can participate in one-on-one meetings by reaching out through their H.C. Wainwright and Lake Street representatives.
When is Elutia's presentation at the H.C. Wainwright conference?
The presentation is scheduled for September 9, 2024, starting at 7:00 a.m. ET.
Where can I get more information about Elutia's products?
More information about Elutia’s products can be found on the company’s official website.
